PHASE 1/2 STUDY OF AP26113 IN PATIENTS (PTS) WITH ADVANCED MALIGNANCIES, INCLUDING ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF SAFETY AND EFFICACY AT SELECTED PHASE 2 DOSES

被引：2
|
作者：
Rosell, R. [1 ]
Gettinger, S. [2 ]
Bazhenova, L. A. [3 ]
Langer, C. J. [4 ]
Salgia, R. [5 ]
Gold, K. [6 ]
Shaw, A. T. [7 ]
Dorer, D. J. [8 ]
Kerstein, D. [9 ]
Camidge, D. R. [10 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol ICO Badalona, Med Oncol Serv, Badalona, Spain
[2] Yale Univ, Sch Med Med Oncol, Thorac Oncol Program, New Haven, CT USA
[3] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA
[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[5] Univ Chicago, Med Ctr, Thorac Oncol, Chicago, IL 60637 USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[7] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
[8] ARIAD Pharmaceut Inc, Biostat, Cambridge, MA 02139 USA
[9] ARIAD Pharmaceut Inc, Clin Res, Cambridge, MA 02139 USA
[10] Univ Colorado, Ctr Canc, Thorac Oncol, Aurora, CO USA
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv050.3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
99O
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients
    Park, Heae Surng
    Lee, June Koo
    Kim, Dong-Wan
    Kulig, Kimary
    Kim, Tae Min
    Lee, Se-Hoon
    Jeon, Yoon-Kyung
    Chung, Doo Hyun
    Heo, Dae Seog
    LUNG CANCER, 2012, 77 (02) : 288 - 292
  • [42] IMMUNOHISTOCHEMICAL SCREENING FOR ANAPLASTIC LYMPHOMA KINASE (ALK) REARRANGEMENT IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
    Lee, June Koo
    Park, Heae Surng
    Kim, Dong-Wan
    Kulig, Kimary
    Kim, Tae Min
    Lee, Se-Hoon
    Jeon, Yoon-Kyung
    Chung, Doo Hyun
    Heo, Deo Seog
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S294 - S295
  • [43] Expression of anaplastic lymphoma kinase (ALK) in patients with non-small cell lung cancer (NSCLC) in the South of Russia.
    Novikova, Inna Arnoldovna
    Nepomnyashchaya, Evgeniya M.
    Maksimov, Aleksey Yurievich
    Ulianova, Elena Petrovna
    Lazutin, Yury N.
    Anistratov, Pavel A.
    Pyltsin, Sergey P.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [44] ALKConnect: An Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) Patient Insights Network
    Lin, H.
    Pan, X.
    Huang, H.
    Salvatore, G.
    Clarke, S.
    West, H.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S617 - S617
  • [45] VISUAL EFFECTS IN ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH CRIZOTINIB
    Yang, P. -C.
    Salgia, R.
    Solomon, B.
    Shaw, A. T.
    Camidge, D. R.
    Evans, T. L.
    Kim, D. -W.
    Shi, Y.
    Han, J. -Y.
    De Pas, T. M.
    Ou, S. -H. I.
    Bartlett, C. H.
    Wilner, K.
    Reisman, A.
    Iyer, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 44 - 44
  • [46] Integrated biomarker analysis of brigatinib efficacy in anaplastic lymphoma kinase-positive (ALK plus ) non-small cell lung cancer (NSCLC) refractory to alectinib
    Ou, S-H. I.
    Nishio, M.
    Yoshida, T.
    Ahn, M-J.
    Mok, T. S. K.
    Kudou, K.
    Asato, T.
    Yang, H.
    Tong, X.
    Zhang, P.
    Yamamoto, N.
    Kim, E. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1014 - S1015
  • [47] Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC)
    Subramanian, J.
    Moreno, V.
    Bosch-Barrera, J.
    Pikiel, J.
    Kristeleit, R.
    Guo, W.
    Danaee, H.
    Im, E.
    Roda, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S886 - S887
  • [48] Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
    Hao, X.
    Zhang, S.
    Hu, Y.
    Zhuang, W.
    Fang, J.
    Liu, Y.
    Wang, M.
    Si, M.
    Sang, Y.
    Kang, X.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1686 - S1687
  • [49] Efficacy and safety of lorlatinib in patients (pts) with ALK plus non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study
    Shaw, Alice Tsang
    Ou, Sai-Hong Ignatius
    Felip, Enriqueta
    Bauer, Todd Michael
    Besse, Benjamin
    Gadgeel, Shirish M.
    Camidge, D. Ross
    Lin, Chia-Chi
    Seto, Takashi
    Soo, Ross A.
    Chiari, Rita
    James, Leonard P.
    Clancy, Jill S.
    Martini, Jean-Francois
    Abbattista, Antonello
    Pithavala, Yazdi K.
    Solomon, Benjamin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Frequency of anaplastic lymphoma kinase (ALK) positive tumors among African American non-small cell lung cancer (NSCLC) patients.
    Gadgeel, Shirish M.
    Cote, Michele L.
    Bepler, Gerold
    Murphy, Valerie
    Malysa, Agnes
    Wozniak, Antoinette J.
    Sukari, Ammar
    Schwartz, Ann G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345